Purchase this article with an account.
Satoshi Iwamoto, Takehiko Yokomizo, Akira Murakami, Akira Matsuda; Control of mouse allergic conjunctivitis by resolvins. Invest. Ophthalmol. Vis. Sci. 2018;59(9):5574. doi: https://doi.org/.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
Docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA) are the ω3 polyunsaturated fatty acids that are found in fish oil. Resolvins are the metabolites of EPA and DHA. Previous reports showed that resolvins play anti-inflammatory and pro-resolving roles in vasculitis and asthma models in mice. In this study, we investigated the roles of DHA-derived resolvin D1 in allergic conjunctivitis using a mouse experimental allergic conjunctivitis model.
10-12 weeks-old female BALB/c mice were used. Mice were sensitized and challenged for 4 days by ragweed pollen. Resolvin D1 (100 ng) was injected intraperitoneally before sensitization and before each challenge. 24 hours after the last challenge, conjunctival tissue was analyzed by Giemsa staining. Furthermore, serum total IgE and inflammatory cytokines in the conjunctiva were quantified by quantitative-PCR.
The number of infiltrating eosinophil was reduced by resolvin D1 treatment. Expression of Il6 mRNA was attenuated by resolvin D1 treatment. On the other hand, concentration of total IgE and expression of Th2 (Il4, and Il13) cytokines in the conjunctiva were not affected by resolvin D1 treatment.
Resolvin D1 attenuated eosinophil infiltration in a mouse allergic conjunctivitis model. The effect of resolvin is not attributed to reduced total IgE and Th2 cytokine regulation. Resolvin might be a new therapeutic modality for allergic conjunctivitis.
This is an abstract that was submitted for the 2018 ARVO Annual Meeting, held in Honolulu, Hawaii, April 29 - May 3, 2018.
This PDF is available to Subscribers Only